Grigoris Gerotziafas on VTE in MM and BCMA: We Are Pleased to Announce Our New Systematic Review
Grigoris Gerotziafas, Director of the Cancer, Vessels, Biology, and Therapeutics (CaVITE) Research Department, Head of the CRSA at Sorbonne University, shared on LinkedIn
about a recent article he and his colleagues co-authored, adding:
”Venous thromboembolism in patients with multiple myeloma treated with B-cell maturation antigen (BCMA)–directed chimeric antigen receptor (CAR) T-cell therapy: A systematic review.
We are pleased to announce our new systematic review leaded by Dr Pedro Las Casas, Associated Researcher in CaVITE Team – Thrombosis Center (G Gerotziafas), CRSA Sorbonne Univeristy:
This work was conducted by the CaVITE team (CRSA, INSERM, Sorbonne University), in collaboration with expert groups from:
- Hematology Department, University Hospital Morales Meseguer and IMIB/CIBERER, Murcia, Spain
- Faculdade de Medicina, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil
- Loyola University Stritch School of Medicine, Maywood (IL), USA
- Hospital Papa Giovanni XXIII, Bergamo, Italy
- Thrombosis Center, Department of Obstetrics, Gynecology and Perinatal Medicine, Sechenov University, Moscow, Russia
Key message: The reported incidence of venous thromboembolism (VTE) after BCMA-directed CAR T-cell therapy in multiple myeloma is low, but likely underestimated, particularly in real-world studies.
When thrombotic events are actively sought and systematically documented, VTE rates appear comparable to those expected in relapsed/refractory multiple myeloma patients receiving standard thromboprophylaxis.
These findings emphasize the need for stronger methodological rigor in assessing and reporting thrombotic complications in CAR T-cell therapy, rather than supporting definitive conclusions regarding thrombotic safety or prophylaxis adequacy.
Reference:
Las Casas PHFDC, Marco-Ayala J, Lefkou EE, Soares TS, Baghdadi MA, Kempaiah P, Fareed J, Vandreden P, Hungria V, Marchetti M, Falanga A, Garderet L, Gerotziafas G. Venous thromboembolism in patients with multiple myeloma treated with B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy: A systematic review. Br J Haematol. 2026 Feb 1. doi: 10.1111/bjh.70356. Epub ahead of print. PMID: 41622574.”
Title: Venous thromboembolism in patients with multiple myeloma treated with B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy: A systematic review
Authors: Pedro Henrique Fernandes do Carmo Las Casas, Javier Marco-Ayala, Elmina-Eleftheria Lefkou, Thamiris Silva Soares, Mohammed A. Baghdadi, Prakasha Kempaiah, Jawed Fareed, Patrick Vandreden, Vania Hungria, Marina Marchetti, Anna Falanga, Laurent Garderet, Grigoris Gerotziafas
Read the Full Article on BJHaem
Stay updated on all scientific advances with Hemostasis Today.
-
Nov 13, 2026, 03:21Abdul Muqtadir Abbasi: Iron Deficiency Beyond Anemia and the Importance of Finding the Cause
-
Nov 13, 2026, 03:05Marc Carrier: Aspirin vs Anticoagulants for VTE Prevention After Joint Replacement
-
Nov 13, 2026, 02:28Julia Sjöberg: ROCK1 Inhibition and Red Blood Cell Recovery After Chemotherapy
-
Nov 13, 2026, 02:07Tonie Reincke: Understanding Deep Vein Thrombosis and Vascular Health
-
Nov 13, 2026, 01:52Akshita Singh: The Remarkable Process of Blood Clotting
-
Nov 12, 2026, 22:52Milka Koupenova: The Role of Platelet RIG-I in Regulating Thrombotic Responses
-
Nov 12, 2026, 22:50Arun V J: Why Has India Still Not Achieved 100% Voluntary Blood Donation?
-
Nov 12, 2026, 22:49Sickle Cell Disease Deserves to Be Prioritised in Ghana – ISCC
-
Nov 12, 2026, 22:47Samir Kumar Beura: Delighted to Serve as a Topic Editor for a Research Topic in Frontiers in Neuroscience